Literature DB >> 11602184

The gamma subunit of the rod photoreceptor cGMP phosphodiesterase can modulate the proteolysis of two cGMP binding cGMP-specific phosphodiesterases (PDE6 and PDE5) by caspase-3.

M Frame1, K F Wan, R Tate, P Vandenabeele, N J Pyne.   

Abstract

We have investigated whether the proteolysis of members of the cGMP binding phosphodiesterases (PDE6, PDE5A1, and PDE10A2) by caspase-3 is modulated by the gamma inhibitor subunit of PDE6. We show here that purified caspase-3 proteolyses PDE6, an enzyme composed of two nonidentical catalytic subunits (termed alpha and beta) with molecular mass of 88 and 84 kDa. The proteolysis of PDE6 produced a single fragment with a molecular mass of 78 kDa. This corresponds to the possible cleavage of the caspase-3 consensus DFVD site (amino acids: 164-168) in the alpha subunit and leads to a 50% decrease in the cGMP hydrolysing activity of the enzyme. The addition of rod PDEgamma to the incubation completely blocked the cleavage of PDE6 by caspase-3. In contrast, rod PDEgamma converted PDE5A1 (molecular mass of 98 kDa) to a better substrate for caspase-3. This resulted in the formation of four major fragments with molecular mass of 82-83, 67, 43, and 34 kDa. In addition, caspase-3 induced an approximately 80% reduction in the activity of a partially purified preparation of PDE5A1 in the presence of rod PDEgamma. Caspase-3 also cleaved PDE10A2 (molecular mass of 95 kDa) to a single 48-kDa fragment. This was consistent with cleavage of the DLFD site (amino acids: 312-315) in PDE10A2. In contrast with both PDE6 and PDE5A1, rod PDEgamma was without effect on this enzyme. These data show that rod PDEgamma interacts with at least two members of the cGMP binding PDE family (PDE5A1 and PDE6) and can exert differential effects on the cleavage of these enzymes by caspase-3.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11602184     DOI: 10.1016/s0898-6568(01)00193-0

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  5 in total

Review 1.  Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.

Authors:  Adam Lerner; Paul M Epstein
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

2.  SOD and inhaled nitric oxide normalize phosphodiesterase 5 expression and activity in neonatal lambs with persistent pulmonary hypertension.

Authors:  Kathryn N Farrow; Satyan Lakshminrusimha; Lyubov Czech; Beezly S Groh; Sylvia F Gugino; Jonathan M Davis; James A Russell; Robin H Steinhorn
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-04-16       Impact factor: 5.464

3.  An assessment of the role of the inhibitory gamma subunit of the retinal cyclic GMP phosphodiesterase and its effect on the p42/p44 mitogen-activated protein kinase pathway in animal and cellular models of pulmonary hypertension.

Authors:  Fiona Murray; Margaret R MacLean; Nigel J Pyne
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

4.  Identifying genetic interactions associated with late-onset Alzheimer's disease.

Authors:  Charalampos S Floudas; Nara Um; M Ilyas Kamboh; Michael M Barmada; Shyam Visweswaran
Journal:  BioData Min       Date:  2014-12-19       Impact factor: 2.522

Review 5.  Many cuts to ruin: a comprehensive update of caspase substrates.

Authors:  U Fischer; R U Jänicke; K Schulze-Osthoff
Journal:  Cell Death Differ       Date:  2003-01       Impact factor: 15.828

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.